<DOC>
	<DOCNO>NCT01594216</DOCNO>
	<brief_summary>This Phase II investigator-Initiated trial Investigational Drug , Ruxolitinib , combination Exemestane patient estrogen-receptor positive advanced breast cancer . The objective study determine preliminary safety efficacy combination exemestane Ruxolitinib ( INCB018424 ) .</brief_summary>
	<brief_title>Ruxolitinib Estrogen Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Histologicallyconfirmed , invasive metastatic breast cancer . Estrogenreceptor positivity ( define least 5 % stain immunohistochemistry ) either primary breast tumor metastatic biopsy . Postmenopausal status , define : either `` surgical menopause '' via oophorectomy , `` natural menopause '' patient menses previous 12month period . Premenopausal patient render amenorrheaic tamoxifen must serum estradiol level &lt; 30 pg/ml discontinuation tamoxifen . Amenorrheaic premenopausal subject must negative pregnancy test screening ( prior enrollment ) must advise use adequate contraception throughout participation . Prior therapy current malignancy : Patient must 1 ) relapse within 2 year complete adjuvant hormonal therapy nonsteroidal aromatase inhibitor , OR 2 ) fail nonsteroidal aromatase inhibitor metastatic setting . There limit prior chemotherapy hormonal regimen malignancy . At least one measureable lesion RECIST mainly lytic bone lesion absence measurable disease . Boneonly disease allow . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate organ function , define follow : Bilirubin ≤ 1.5 x upper limit normal ( ULN ) Serum creatinine ≤ 1.5 x UNL calculate creatinine clearance ≥ 60 mL/min , For subject without liver metastasis : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN For subject liver metastasis : alanine aminotransferase ( ALT ) aspartate aminotransferase ≤ 5 x ULN Adequate bone marrow function , define follow Absolute neutrophil count ( ANC ) &gt; 1500/mm3 Hemoglobin &gt; 9 Platelets &gt; 100,000/mm3 The subject capable understanding comply protocol requirement sign informed consent document . EXCLUSION CRITERIA : Chemotherapy , hormonal therapy investigational antitumor therapy within 21 day start study treatment . Use bonebuilding agent allow . Prior treatment exemestane . Any type investigational agent within 28 day first dose study treatment . Unresolved clinicallymeaningful toxicity due prior therapy . Toxicity previous treatment must back baseline Grade ≤ 1 , exception neurotoxicity alopecia . Untreated uncontrolled brain metastasis evidence leptomeningeal involvement disease . Patients stable disease radiotherapy CNS disease eligible . Testing brain involvement absence symptom require part protocol . Uncontrolled , intercurrent illness Known ongoing active infection , include active hepatitis B hepatitis C. Testing hepatitis B C require part protocol . Uncontrolled diabetes mellitus Uncontrolled hypertension Symptomatic congestive heart failure , unstable angina pectoris , stroke myocardial infarction within 3 month A baseline correct QT interval ( QTc ) &gt; 470 m . The subject know positive human immunodeficiency virus ( HIV ) . Note : baseline HIV screening require The subject unable unwilling abide study protocol cooperate fully investigator designee .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Postmenopausal female</keyword>
</DOC>